AAAAAA
Results:
1-24
|
Results: 24
Authors:
Seregni, E
Ferrari, L
Bajetta, E
Martinetti, A
Bombardieri, E
Citation: E. Seregni et al., Clinical significance of blood chromogranin A measurement in neuroendocrine tumours, ANN ONCOL, 12, 2001, pp. S69-S72
Authors:
Van Cutsem, E
Twelves, C
Cassidy, J
Allman, D
Bajetta, E
Boyer, M
Bugat, R
Findlay, M
Frings, S
Jahn, M
McKendrick, J
Osterwalder, B
Perez-Manga, G
Rosso, R
Rougier, P
Schmiegel, WH
Seitz, JF
Thompson, P
Vieitez, JM
Weitzel, C
Harper, P
Citation: E. Van Cutsem et al., Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study, J CL ONCOL, 19(21), 2001, pp. 4097-4106
Authors:
Littlewood, TJ
Bajetta, E
Nortier, JWR
Vercammen, E
Rapoport, B
Citation: Tj. Littlewood et al., Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized,double-blind, placebo-controlled trial, J CL ONCOL, 19(11), 2001, pp. 2865-2874
Authors:
Bajetta, E
Del Vecchio, M
Vitali, M
Martinetti, A
Ferrari, L
Queirolo, P
Sertoli, MR
Cainelli, T
Cellerino, R
Cascinelli, N
Citation: E. Bajetta et al., A feasibility study using polychemotherapy (cisplatin plus vindesine plus dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma, TUMORI, 87(4), 2001, pp. 219-222
Authors:
Bajetta, E
Bichisao, E
Artale, S
Celio, L
Ferrari, L
Di Bartolomeo, M
Zilembo, N
Stani, SC
Buzzoni, R
Citation: E. Bajetta et al., New clinical trials for the treatment of neuroendocrine tumors, Q J NUCL M, 44(1), 2000, pp. 96-101
Authors:
Bajetta, E
Zilembo, N
Bichisao, E
Pozzi, P
Toffolatti, L
Citation: E. Bajetta et al., Steroidal aromatase inhibitors in elderly patients, CR R ONC H, 33(2), 2000, pp. 137-142
Authors:
Martinetti, A
Ferrari, L
Celio, L
Mariani, L
Miceli, R
Zilembo, N
Di Bartolomeo, M
Toffolatti, L
Pozzi, P
Seregni, E
Bombardieri, E
Bajetta, E
Citation: A. Martinetti et al., The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers, J STEROID B, 75(1), 2000, pp. 65-73
Authors:
Kaufmann, M
Bajetta, E
Dirix, LY
Fein, LE
Jones, SE
Cervek, J
Fowst, C
Polli, A
Di Salle, E
Massimini, G
Piscitelli, G
Citation: M. Kaufmann et al., Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: results of a double-blind randomised phase III trial, EUR J CANC, 36, 2000, pp. S86-S87
Authors:
Bajetta, E
Zilembo, N
Bichisao, E
Martinetti, A
Buzzoni, R
Pozzi, P
Bidoli, P
Ferrari, L
Celio, L
Citation: E. Bajetta et al., Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors, ANN ONCOL, 11(8), 2000, pp. 1017-1022
Authors:
Kaufmann, M
Bajetta, E
Dirix, LY
Fein, LE
Jones, SE
Zilembo, N
Dugardyn, JC
Nasurdi, C
Mennel, RG
Cervek, J
Fowst, C
Polli, A
di Salle, E
Arkhipov, A
Piscitelli, G
Miller, LL
Massimini, G
Citation: M. Kaufmann et al., Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial, J CL ONCOL, 18(7), 2000, pp. 1399-1411
Authors:
Lonning, PE
Bajetta, E
Murray, R
Tubiana-Hulin, M
Eisenberg, PD
Mickiewicz, E
Celio, L
Pitt, P
Mita, M
Aaronson, NK
Fowst, C
Arkhipov, A
di Salle, E
Polli, A
Massimini, G
Citation: Pe. Lonning et al., Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial, J CL ONCOL, 18(11), 2000, pp. 2234-2244
Authors:
Celio, L
Bajetta, E
Toffolatti, L
Catena, L
Beretta, E
Buzzoni, R
Citation: L. Celio et al., Ovarian ablation for premenopausal early-stage breast cancer: An update, TUMORI, 86(3), 2000, pp. 191-194
Authors:
Salvadori, B
Celio, L
Oriana, R
Bajetta, E
Citation: B. Salvadori et al., Adjuvant oophorectomy versus CMF in premenopausal node-positive breast cancer: Long-term results of an experience at the Milan Cancer Institute, TUMORI, 86(3), 2000, pp. 258-259
Authors:
Mortarini, R
Borri, A
Tragni, C
Bersani, I
Vegetti, C
Bajetta, E
Pillotti, S
Cerundolo, V
Anichini, A
Citation: R. Mortarini et al., Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8(+) T cells in melanoma patients receiving interleukin 12, CANCER RES, 60(13), 2000, pp. 3559-3568
Authors:
Bajetta, E
Stani, SC
De Candis, D
Bidoli, P
Mariani, L
Zilembo, N
Pozzi, P
Procopio, G
Citation: E. Bajetta et al., Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a Phase II trial, CANCER, 89(4), 2000, pp. 763-768
Authors:
Bajetta, E
Zilembo, N
Bichisao, E
Citation: E. Bajetta et al., Aromatase inhibitors in the treatment of postmenopausal breast cancer, DRUG AGING, 15(4), 1999, pp. 271-283
Authors:
Bajetta, E
Zilembo, N
Dowsett, M
Guillevin, L
Di Leo, A
Celio, L
Martinetti, A
Marchiano, A
Pozzi, P
Stani, S
Bichisao, E
Citation: E. Bajetta et al., Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients, EUR J CANC, 35(2), 1999, pp. 208-213
Authors:
Bajetta, E
Di Bartolomeo, M
Stani, SC
Artale, S
Ricci, SB
Bozzetti, F
Mazzaferro, V
Toffolatti, L
Buzzoni, R
Citation: E. Bajetta et al., Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: Results of a feasibility study, INT J RAD O, 45(2), 1999, pp. 285-289
Authors:
Di Bartolomeo, M
Bajetta, E
Buzzoni, R
Bozzetti, F
Artale, S
Valvo, F
Citation: M. Di Bartolomeo et al., Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility study, TUMORI, 85(3), 1999, pp. 211-213
Authors:
Del Vecchio, M
Procopio, G
Cassata, A
Pozzi, P
Busto, G
Celio, L
Bajetta, E
Citation: M. Del Vecchio et al., Fluoropyrimidines in the treatment of advanced neoplastic diseases: Role and advantages of UFT, TUMORI, 85(1), 1999, pp. 6-11
Authors:
Zampino, MG
Colleoni, M
Bajetta, E
Stampino, CG
Guenzi, A
de Braud, F
Citation: Mg. Zampino et al., Pharmacokinetics of oral doxifluridine in patients with colorectal cancer, TUMORI, 85(1), 1999, pp. 47-50
Authors:
Ferrari, L
Seregni, E
Bajetta, E
Martinetti, A
Bombardieri, E
Citation: L. Ferrari et al., The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours, ANTICANC R, 19(4C), 1999, pp. 3415-3427
Authors:
Celio, L
Martinetti, A
Ferrari, L
Buzzoni, R
Mariani, L
Miceli, R
Seregni, E
Procopio, G
Cassata, A
Bombardieri, E
Bajetta, E
Citation: L. Celio et al., Premenopausal breast cancer patients treated with a gonadotropin-releasinghormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study, ANTICANC R, 19(3B), 1999, pp. 2261-2268
Authors:
Bajetta, E
Ferrari, L
Martinetti, A
Celio, L
Procopio, G
Artale, S
Zilembo, N
Di Bartolomeo, M
Seregni, E
Bombardieri, E
Citation: E. Bajetta et al., Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors, CANCER, 86(5), 1999, pp. 858-865
Risultati:
1-24
|